Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 14;10(7):2461-2465.
doi: 10.1016/j.ekir.2025.04.012. eCollection 2025 Jul.

Finerenone and Estimated GFR Slope in Type 2 Diabetes and CKD

Masayuki Yamanouchi  1   2   3   4   5 , Yuki Oba  2 , Hisashi Kamido  2 , Masatoshi Yoshimoto  2 , Yusuke Yoshimura  2 , Hisashi Sugimoto  2 , Shigekazu Kurihara  2 , Akinari Sekine  1 , Tatsuya Suwabe  1   2 , Naoki Sawa  1   2 , Takehiko Wada  1 , Kengo Furuichi  5 , Takashi Wada  4 , Yoshifumi Ubara  1   2
Affiliations

Finerenone and Estimated GFR Slope in Type 2 Diabetes and CKD

Masayuki Yamanouchi et al. Kidney Int Rep. .
No abstract available

Keywords: chronic kidney disease; eGFR slope; finerenone; nonsteroidal mineralocorticoid receptor (MR) antagonist; real-world study; type 2 diabetes mellitus.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Longitudinal changes in eGFR before and after finerenone initiation. This figure illustrates the longitudinal changes in mean eGFR (± SE) before and after finerenone initiation, with the mean eGFR at month 0 centered to 0. The eGFR slope during the posttreatment period was calculated from 1 month after finerenone initiation to exclude the acute drop in eGFR observed during the first month. Following an acute drop of 0.96 ml/min per 1.73 m2 (95% CI: 0.04–1.88), equivalent to a 2.3% decline (95% CI: 0.1–4.5), the eGFR slope improved from −4.12 ml/min per 1.73 m2/yr (95% CI: −4.84 to −3.40) to −1.83 ml/min per 1.73 m2/yr (95% CI: −2.22 to −1.43). The improvement in eGFR slope was 2.29 ml/min per 1.73 m2/yr (95% CI: 1.59–3.00, P < 0.001). Linear mixed-effects models for repeated measures were used to estimate these slopes, with additional details provided in the Supplementary Methods section. CI, confidence interval; eGFR, estimated glomerular filtration rate; SE, standard error.
Figure 2
Figure 2
Longitudinal changes in eGFR before and after finerenone initiation by baseline eGFR and albuminuria categories. (a) Longitudinal changes in mean eGFR (± SE) before and after finerenone initiation, stratified by baseline eGFR category. (b) Longitudinal changes in mean eGFR (± SE) before and after finerenone initiation, stratified by baseline albuminuria category. Finerenone improved the eGFR slope regardless of baseline eGFR or albuminuria category. ACR, urine albumin-to-creatinine ratio; eGFR, estimated glomerular filtration rate.
See this image and copyright information in PMC

References

    1. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102:S1–S127. doi: 10.1016/j.kint.2022.06.008. - DOI - PubMed
    1. Bakris G.L., Agarwal R., Anker S.D., et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219–2229. doi: 10.1056/NEJMoa2025845. - DOI - PubMed
    1. Pitt B., Filippatos G., Agarwal R., et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385:2252–2263. doi: 10.1056/NEJMoa2110956. - DOI - PubMed
    1. Georgianos P.I., Agarwal R. Mineralocorticoid receptor antagonism in chronic kidney disease. Kidney Int Rep. 2021;6:2281–2291. doi: 10.1016/j.ekir.2021.05.027. - DOI - PMC - PubMed
    1. Inker L.A., Collier W., Greene T., et al. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure. Nat Med. 2023;29:1867–1876. doi: 10.1038/s41591-023-02418-0. - DOI - PubMed

LinkOut - more resources